Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, including Annamycin, a next-generation anthracycline for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML, and WP1122, an antimetabolite for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. The company is also developing WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin Biotech has three core technologies: Annamycin, Immune/Transcription Modulators, and Metabolism/Glycosylation Inhibitors, and is engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.